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VeteransBackground:GulfWar Illness (GWI) is a disease of unknown etiologywith symptoms suggesting the involvement
of an immune process. Here we tested the hypothesis that Human Leukocyte Antigen (HLA) composition might
differ between veterans with and without GWI.
Methods:We identiﬁed 144 unique alleles of Class I and II HLA genes in 82 veterans (66 with and 16 without
GWI). We tested the hypothesis that a subset of HLA alleles may classify veterans in their respective group
using a stepwise linear discriminant analysis. In addition, each participant rated symptom severity in 6 domains
according to established GWI criteria, and an overall symptom severity was calculated.
Findings:We found 6 Class II alleles that classiﬁed participants 84.1% correctly (13/16 control and 56/66 GWI).
The number of copies of the 6 alleles was signiﬁcantly higher in the control group, suggesting a protective role.
This was supported by a signiﬁcant negative dependence of overall symptom severity on the number of allele
copies, such that symptom severity was lower in participants with larger numbers of allele copies.
Interpretation: These results indicate a reduced HLA protection (i.e. genetic susceptibility) in veterans with GWI.
Funding: University of Minnesota and U.S. Department of Veterans Affairs.
Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Shortly after the Gulf War (1990–91), veterans started to report a va-
riety of health problems that began during, or soon after returning from,
deployment, prompting investigation into the epidemiology and etiology
of the complaints. Those investigations revealed that diffuse symptoms
such as fatigue, musculoskeletal pain, mood and neurocognitive com-
plaints, gastrointestinal problems, and rashes were most commonly
reported. The constellation of symptoms, now commonly referred to as
GulfWar Illness (GWI), has affected a substantial number of GulfWar vet-
erans (Fukuda et al., 1998; Institute of Medicine, 2006, 2010; Kang et al.,
2009; Steele, 2000). Several population-based studies have demonstrated
that these symptoms occur at signiﬁcantly higher rates in deployed Gulf
War veterans relative to their nondeployed peers and other veterans
(Fukuda et al., 1998; Kelsall et al., 2009; Unwin et al., 1999), raising the1B), Minneapolis VAHCS, One
.
ss article under the CC BY license (htissue about possible in-theater exposures and stress as contributing fac-
tors. However, these symptoms are also present in non-deployedmilitary
personnel (Steele, 2000), leading some to suspect other causes, including
reactions to vaccine adjuvants (Israeli, 2012; Toubi, 2012). In summary,
GWI is now a recognized constellation of symptoms of unclear etiology,
also co-occurring with psychiatric disorders.
To date, the pathophysiology of GWI remains poorly understood.
The overlap of GWI symptoms with symptoms of autoimmune disor-
ders (e.g., chronic fatigue), togetherwith evidence of abnormal immune
activation following exercise challenge (Broderick et al., 2012, 2013),
raise the possibility that GWI reﬂects an abnormal immune process
(Broderick et al., 2012, 2013; Hotopf et al., 2000; Israeli, 2012; Moss,
2013; Toubi, 2012). This probable involvement of altered immune
mechanisms prompted our investigation of Human Leukocyte Antigen
(HLA) in GWI.
HLA genes are located in the Major Histocompatibility Complex
(MHC) of chromosome 6 and play a central role in immune recognition
(Meuer et al., 1982).Most investigations of association of HLA to varioustp://creativecommons.org/licenses/by/4.0/).
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of interest, as compared to the general, healthy population. Such studies
have demonstratedHLA involvementwith cancer, autoimmune, and in-
fectious diseases (Rioux et al., 2009; Trowsdale and Knight, 2013). HLA
Class I proteins (HLA-A, B, C) are expressed on all nucleated cells and
present peptides from endogenous proteins to cytotoxic T lymphocytes
engaged in immune surveillance. HLA Class II proteins (HLA-DRB1,
DRB3/4/5, DQB1, DPB1) are expressed on antigen-presenting cells and
present peptides derived from exogenous proteins to CD4+ helper T
cells (Reche and Reinherz, 2003). A previous study of Gulf War syn-
drome in 27 veterans found that HLA DRB1*15 was more prevalent in
cases than controls with an odds ratio of 1.66, although this association
was not statistically signiﬁcant (O'Bryan et al., 2003).
Here we tested the hypothesis that HLAmay be a contributing factor
in developing GWI by performing a stepwise linear discriminant analy-
sis which assessed how well the number of copies of HLA alleles could
classify participants in their respective group.
2. Materials and Methods
2.1. Study Participants
Veterans Affairs (VA) medical records were reviewed to identify po-
tential participants. Participants were recruited if they had completed a
Gulf War physical or if they had served during the Persian Gulf War.
Exclusionary criteria included central nervous system disorders (e.g.
Parkinson's disease, dementia, cerebral vascular accidents, a history of
traumatic brain injury, etc.), lifetime psychotic or bipolar diagnoses,
and current drug dependence. Veterans who might have had difﬁculty
understanding the protocol were also excluded from recruitment. Par-
ticipants provided written informed consent prior to participation and
were compensated for their time. The study protocol was approved by
the Institutional Review Board at the Minneapolis VA Health Care
System.
We studied a total of 82 participants, 16 controls (15men, 1woman;
age range 43–71 years; 54.9 ± 10.2 years, mean± SD) and 66 GWI (64
men, 2women; age range 39–76 years; 50.6± 7.9 years). Themean age
did not differ signiﬁcantly between the 2 groups (P = 0.13, t-test).
Participants completed a symptom presence/severity questionnaire
developed for use in Kansas Gulf War veterans (Steele, 2000) that eval-
uates a range of symptomsassociatedwithGWI andpermits determina-
tion of case status according to either the Centers for Disease Control
and Prevention (CDC) criteria (Fukuda et al., 1998) or the Kansas GWI
case deﬁnition (Steele, 2000). Participants meeting either set of Gulf
War case deﬁnition criteria were included in the study. All participants
had deployed during the Gulf War and were free of any autoimmune
disease.
The questionnaire asks participants to indicate if they have had a
persistent problem over the last 6 months with various symptoms
from the following six domains: fatigue, pain, neurological-cognitive-
mood, skin, respiratory, and gastrointestinal. For each symptom rated
as present, participants are asked to rate the severity of the symptom
as mild, moderate, or severe, and to indicate whether the symptom
ﬁrst became problematic before, during or after deployment to the
Gulf. Only symptoms that began during or after Gulf War service are
counted toward diagnosis. There were six symptom domains: fatigue,
pain, neurological-cognitive-mood, skin, gastrointestinal, and respirato-
ry (Steele, 2000). Individual symptom severity was reported in a scale
from 0 to 3. For each participant, an average score per domain was cal-
culated, and a grand average across domainswas used in the regression
analysis below.
2.2. HLA Genotyping
DNA isolation was carried out from 3 ml of whole blood drawn
in EDTA tubes, using a commercially available kit (ArchivePurecat. 2,300,730) from 5Prime (distributed by Fisher Scientiﬁc or
VWR) with an expected yield of 50-150 μg of DNA. The puriﬁed
DNA samples were sent to Histogenetics (http://www.histogenetics.
com/) for high-resolution HLA Sequence-based Typing (SBT; details are
given in https://bioinformatics.bethematchclinical.org/HLA-Resources/
HLA-Typing/High-Resolution-Typing-Procedures/ and https://
bioinformatics.bethematchclinical.org/WorkArea/DownloadAsset.
aspx?id=6482). Their sequencing DNA templates are produced by
locus- and group-speciﬁc ampliﬁcations that include exon 2 and 3 for
class I (A, B, C) and exon 2 for class II (DRB1, DRB3/4/5, DQB1, and
DPB1) and reported as Antigen Recognition Site (ARS) alleles as per
ASHI recommendation (Cano et al., 2007).2.3. Data Analysis
Standard statistical tests were used to analyze the data using the
IBM-SPSS statistical package (version 23) and ad hoc Fortran computer
programs employing the International Mathematics and Statistics Li-
brary (IMSL; Rogue Wave Software, Louisville, CO, USA) statistical and
mathematical libraries. We performed a stepwise linear discriminant
analysis to identify those alleles that would correctly classify partici-
pants to their respective groups (control, GWI) using the SPSS statistical
package above. In that analysis, group membership was the classiﬁca-
tion variable and the numbers of copies for each allele for each partici-
pant were the predictor variables (N = 144 alleles). This analysis
identiﬁed 6 alleles that, as a group, classiﬁed correctly 84.1% of the par-
ticipants (see below). We validated the robustness of this allele set by
calculating the classiﬁcation rate using the leave-one-out method in
the original sample and by performing an extensive analysis based on
the bootstrap (Efron and Tibshirani, 1993), as follows. Each participant
was classiﬁed 10,000 times using bootstrap samples of participants
and associated data from the 6 alleles above as predictors. Speciﬁcally,
each bootstrap sample was generated by random sampling with re-
placement from each one of the 2 groups (control and GWI) to a total
of N=200 participant values per group (in separate additional analysis,
bootstrap samples of N = 100 participants were used). We then per-
formed a linear discriminant classiﬁcation analysis to classify the given
participant to one of the 2 groups, based on the 2 bootstrapped partici-
pant samples. Finally, we calculated the correct classiﬁcation rate for
each group. The quality and strength of classiﬁcation was assessed
using standard methods, including chi-square analysis, calculating con-
ﬁdence intervals on the sensitivity and speciﬁcity using the binomial
theorem andWilson's conservative test (Wilson, 1927), and calculating
the receiver operating characteristic (ROC) curve and its associated
statistics.
A different issue concerns the possible effect of unequal group
sizes on the results of the discriminant analysis (Sanchez, 1974). Ide-
ally, the group sizes should be equal, or as closely equal as possible,
because, then, the null hypothesis for chance classiﬁcation is the
same or very similar across groups. To remedy this sample inequali-
ty, Sanchez (1974) proposed the following procedure aimed to per-
form the discriminant analysis using the same (or very similar)
sample sizes. Let G1 and G2 be two groups to be discriminated with
sample sizesm and km, respectively. The standard discriminant anal-
ysis would be somewhat hampered by the unequal sample sizes,
kmNm. To remedy this, Sanchez (1974) proposed that, instead of a
single discriminant analysis, k such analyses be performed, where
one group is always the same N(G1)=m, whereas the other group
is a random subsample (without replacement) from G2, of size NðG2
Þ ¼ kmk ¼ m, i.e. the same to that of G1, with equal chance probabilities
of 0.5. The ﬁnal classiﬁcation rate is the average of the k classiﬁcation
outcomes. We applied this approach to our data as follows. The sam-
ple size of the control group was 16, and that of the GWI was 66.
Since 66 cannot be divided exactly by 16, we performed the follow-
ing steps.
Table 1
Distribution of 144 HLA 4-digit resolution unique alleles identiﬁed to corresponding
genes.
Class Gene Count Percent
II A 19 13.2
II B 36 25.0
II C 19 13.2
II DRB1 29 20.1
II DRB3 3 2.1
II DRB4 1 0.7
II DRB5 3 2.1
II DQB1 15 10.4
II DPB1 19 13.2
Total 144 100.0
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of the two groups to be classiﬁed.
Step 2: The original GWI group (N= 66) was randomly permuted.
Step 3: Four consecutive subsamples of n = 16 each were identiﬁed
and four discriminant analyses performed between the original con-
trol group and each subsample above. This yielded four classiﬁcation
rates the average of which provided an overall classiﬁcation rate
against a chance probability of 0.5, since sample sizes were equal.
Step 4: This procedure left out two participants from the GWI group.
To remedy this, we performed Steps 2 and 3 10,000 times, eachwith
a different permutation. In thisway, all GWI participants contributed
to the analysis.
Step 5: The ﬁnal classiﬁcation rate was derived as the average of the
10,000 rates above and its value assessed against the expected
chance rate of 0.5 (50%).
We assessed the direction of the effect of those alleles (protective vs.
predisposing) by carrying out four additional analyses. First, we com-
pared the frequencies of those alleles between the two groups using a
paired t-test. Second, we calculated the odds ratio (ω) for each allele,
took its natural logarithm, ln(ω), and tested the null hypothesis that
its average does not differ signiﬁcantly from zero, using a one-sample
t-test. (If any cell in the 2 × 2 table had zero counts, the odds ratio
was calculated after the constant 0.5 was added to all counts in the
table, to avoid taking the logarithm of zero or dividing by zero.) Third,
we performed a linear regression analysis where the overall symptom
severity was the dependent variable and the number of copies of the 6
alleles was the independent variable; this analysis was also performed
separately for each symptom domain. Signiﬁcantly lower average allele
frequencies in GWI, a signiﬁcant negative ln(ω) and a signiﬁcant nega-
tive slope (and correlation) in the regression analysis would argue for a
collective protective effect of the 6 alleles. Finally, we compared the
frequencies of those 6 alleles in our two groups (GWI, controls) to the
frequencies that have been reported in the literature. Speciﬁcally, we
searched the website “Allele*Frequencies in Worldwide Populations”
(http://www.allelefrequencies.net/) and identiﬁed the following three
databases on Caucasian populations from the United States with 4-
digit HLA genotyping of the 3 relevant Class II loci (DQB1, DPB1,
DRB1): (1) “USA San Francisco Caucasian” (SF; N = 220; Skibola et al.,
2012); (2) “USA Minnesota Olmsted” (MN; N = 339; Ovsyannikova
et al., 2005); and (3) “USA Caucasian pop 5” (source: Center for Disease
Control, CDC; N = 268; Rossman et al., 2003). Analyses and compari-
sons with our data were carried out separately for each one of the 3
databases above.
2.4. Role of the Funding Source
Partial funding for this study was provided by the US Department of
Veterans Affairs (Service Directed Research Program, Project Number
3106) and the University of Minnesota (Brain and Genomics Fund [Uni-
versity of Minnesota Foundation Fund Number 20507] and the
American Legion Brain Sciences Chair [University of Minnesota Founda-
tion Fund Number 20442]). The sponsors had no role in the current
study design, analysis or interpretation, or in the writing of this paper.
The contents do not represent the views of the U.S. Department of Vet-
erans Affairs or the United States Government.
3. Results
A total of 144 unique HLA alleles (74 Class I and 70 Class II, Table 1)
were identiﬁed from a total of 82 participants. The stepwise linear dis-
criminant analysis identiﬁed 6 alleles that yielded 84.1% correct classiﬁ-
cation of the 82 subjects to their respective groups. These results were
robust. The leave-one-out classiﬁcation rate for the original sample
was 79.1% and for the 2 bootstrap analyses N80% (80.1% for bootstrapsamples of N = 100 and 81.2% for N = 200). We also performed the
same stepwise discriminant analysis in a gender-homogeneous sample
for men only (N=79). The correct classiﬁcation rate was 86.1% and the
leave-one-out classiﬁcation rate was 81.0%. The overall classiﬁcation
rate obtained by applying the procedure proposed by Sanchez (1974)
(see Methods) was 82.3% (range: 78.1%–85.9%, N = 10,000 permuta-
tions), which is way substantially and consistently above the expected
chance rate of 50%.
The alleles and associated statistics are given in Table 2 and details
about the goodness of classiﬁcation based on the results using the full
GWI sample are presented in Table 3. It can be seen that the discrimi-
nant classiﬁcation was highly statistically signiﬁcant and effective, and
that the classiﬁcation was correct at a high level (N80%), was very sim-
ilar with respect to sensitivity (0.848; 84.8%) and speciﬁcity (0.812;
81.2%), exceeded chance even by the most conservative Wilson's test
(Table 3E), and yielded a ROC curve (Fig. 1) that was highly signiﬁcant
and considerably above chance (Table 3F).
The analysis of frequencies of the 6 alleles (Table 4, A, B) pointed to a
systematic protective effect in the control group and, by extension, lack
of protection in the GWI group. This is evidenced by the fact that all
allele frequencieswere lower in the GWI group (Table 4A), as compared
to the control group (t =−5.789, DF = 5, P = 0.002, paired t-test)
and that all the odds ratios were less than one, i.e. negative ln(ω):
ln(ω) = −1.792 ± 0.383 (mean ± SEM), t = −4.671, DF = 5,
P = 0.005, one-sample t-test against the null hypothesis that mean
ln(ω) = 0). In addition, the percentage of participants with a given
allele was systematically lower for all 6 alleles (Table 4B).
This collective protective effect of the 6 alleles abovewas further cor-
roborated by the results of the linear regression of overall symptom se-
verity against the number of allele copies (Fig. 2) which revealed a
strong and highly signiﬁcant negative relation (t =−4.148, DF = 80,
P = 0.000083, R2 = 0.177):
GWI symptom severity ¼ 4:55−2:044 number of 6 allele copies ð1Þ
We also performed a multiple linear regression analysis separately
for each symptom domain. We found a highly signiﬁcant effect of the
number of copies of individual alleles on symptom severity of Pain
(P = 0.01, R2 = 0.199), Fatigue (P = 0.006, R2 = 0.210), and
Neurological-Cognitive-Mood (P = 0.004, R2 = 0.225) symptoms; re-
markably, all slopes (i.e. partial regression coefﬁcients) of individual al-
lele copies vs. symptom severity were negative in each regression
model, indicating a consistent and robust effect. Finally, the regression
analysis was not signiﬁcant for skin (P = 0.911), gastrointestinal (P =
0.576), and respiratory (P = 0.598) symptoms.
Next, we analyzed our data with respect to the three databases (SF,
MN, CDC) from the literature. Fig. 3 shows the mean frequencies across
the 6 alleles as found in the3 databases, our controls and theGWI group.
It can be seen that the values for the 3 databases are similar, whereas the
values for the GWI and control groups are lower and higher, respective-
ly, than those of the databases. Next, we carried out a statistical analysis
Table 2
The six HLA alleles identiﬁed by the stepwise linear discriminant analysis and associated
statistics. All alleles are from Class II.
A. Stepwise statistics
Allele Tolerance F-to-remove Wilks'
Lambda
1 DQB1*02:02 0.934 12.942 0.749
2 DPB1*06:01 0.913 10.162 0.725
3 DRB1*13:02 0.872 11.446 0.736
4 DRB1*08:11 0.943 8.249 0.709
5 DRB1*01:01 0.904 5.329 0.684
6 DPB1*01:01 0.923 4.228 0.675
B. Canonical discriminant function statistics
Eigenvalue % of variance Cumulative %
0.565 100 100
Wilks' Lambda Chi-square DF Signiﬁcance
0.639 34.5 6 0.000005
Fig. 1. ROC curve of classiﬁcation by the six discriminating alleles. AUC, Area Under the
Curve. The asymptotic standard error of the AUCwas 0.062; P= 0.00004; 95% conﬁdence
intervals for the AUC: 0.708–0.953.
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base and control, and each database and GWI populations. This yielded
6 alleles × 3 databases × 2 groups = 36 values. We assessed the main
effects of Database and Group, and the Database × Group interactions
by performing a univariate ANOVA. We found that the Group main ef-
fect was highly signiﬁcant (Fig. 4; P = 0.00019), whereas neither the
Database main effect (P = 0.911; data not shown) nor the
Database × Group interaction (Fig. 5; P = 0.934) were statistically sig-
niﬁcant (F-test in the ANOVA). These results document the signiﬁcant
difference between the control (increased) and GWI (decreased)Table 3
Classiﬁcation results.
A. Classiﬁcation table
Predicted Total
GWI Control
Observed GWI 56 10 66
Control 3 13 16
Total 59 23 82
B. Analysis of the two-way classiﬁcation table
Test Value DF Signiﬁcance
(2-sided)
Pearson Chi-Square
(corrected for continuity)
27.9 1 P = 1.29 × 10−7
Fisher's Exact Test P = 9.25 × 10−7
C. Mantel–Haenszel common odds ratio estimate
Estimated odds ratio (ω) ln(ω) SE of ln(ω) Asymptotic signiﬁcance
(2-sided)
24.267
95% lower bound: 5.840
95% upper bound: 100.83
3.189 0.727 P = 0.000011
D. Sensitivity, speciﬁcity, and binomial conﬁdence intervals
Observed 95% conﬁdence intervals
Lower bound Upper bound
Sensitivity 0.848 (84.8%) 0.804 0.893
Speciﬁcity 0.812 (81.2%) 0.715 0.910
E. Sensitivity, speciﬁcity, and Wilson's (1927) conﬁdence intervals
Observed 95% conﬁdence intervals
Lower bound Upper bound
Sensitivity 0.848 0.702 0.888
Speciﬁcity 0.812 0.570 0.934mean allele frequencies, relative to the 3 databases, while positing the
similarity among the 3 databases and the similarity of the group effect
across these databases.
Finally, we searched the “Allele*Frequencies in Worldwide Popula-
tions” (http://www.allelefrequencies.net/) website for known haplo-
types related to the 6 discriminating alleles, within the 3 databases
that we used. Haplotype information was available only for the SF data-
base, as shown in Table 5. It can be seen that no identiﬁed haplotype
contains more than one of the 6 discriminating alleles, indicating their
unique contribution.
4. Discussion
These results document for the ﬁrst time signiﬁcant differences in
theHLAmakeup between veteranswith GWI andGulfWar era veterans
without it. All the evidence from this study points to an enhanced vul-
nerability (or lack of protection) of the GWI veterans and, conversely,
a reduced vulnerability (or additional protection) of the healthy
veterans who served in the Gulf War but did not suffer from GWI. Col-
lectively, our ﬁndings are in keepingwith other evidence for an immuneTable 4
Frequency analysis of the 6 discriminating alleles.
A. Frequencies and odds ratios
Allele GWI
frequency
Control
frequency
Estimated
odds ratio (ω)
ln(ω)
1 DQB1*02:02 0 0.0625 0.046a −3.078
2 DPB1*06:01 0.007576 0.0625 0.114 −2.167
3 DRB1*13:02 0.0379 0.125 0.276 −1.289
4 DRB1*08:11 0 0.0312 0.0792a −2.535
5 DRB1*01:01 0.0682 0.1562 0.395 −0.927
6 DPB1*01:01 0.0303 0.0625 0.469 −0.758
B. Percent of participants per group and allele
Allele GWI Control
1 DQB1*02:02 0 12.5
2 DPB1*06:01 1.5 12.5
3 DRB1*13:02 7.6 25
4 DRB1*08:11 0 6.3
5 DRB1*01:01 13.6 18.8
6 DPB1*01:01 6.1 12.5
a The odds ratio was estimated after adding 0.5 to all counts to avoid taking the loga-
rithm of zero. This procedure underestimates the true effect.
Fig. 2.Mean GWI symptom severity is plotted against the average number of copies of the
six discriminating alleles. N denotes the number of participants. (See text for details.)
Fig. 4.Mean ln(ω) (± SEM) for the control and GWI groups across the three databases.
(See text for details.)
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Hotopf et al., 2000; Israeli, 2012; Moss, 2013; Toubi, 2012; Whistler
et al., 2009), in addition to other factors, including inﬂammatory com-
ponents (Broderick et al., 2012, 2013; Johnson et al., 2013), mitochon-
dria dysfunction (Koslik et al., 2014) and genetic variants regarding
butyrylcholinesterase enzyme activity (Steele et al., 2015). In fact, our
ﬁndings provide a genetic susceptibility framework within which envi-
ronmental triggers (e.g. vaccines, exposure to chemicals, stress, etc.) can
be discussed, investigated and evaluated.
All six HLA alleles that were singled out by the discriminant analysis
to classify successfully (Fig. 1) control and GWI participants belonged in
Class II and came from all three major genes (DQB1, DPB1, DRB1). Two
alleles (DQB1*02:02 and DRB1*08:11) were absent from the GWI pop-
ulation, and the frequencies of the remaining four were all lower in the
GWI group than in the control group (Table 4A). In addition, the per-
centage of participants with any of the six alleles was lower than in
the controls (Table 4B). These results, together, document the lower fre-
quency of occurrence of these alleles in the GWI group, as compared to
the control group. The results of the regression analysis further docu-
mented the protective association of those alleles, given the signiﬁcant
negative slope in Fig. 2. In addition, this analysis further differentiated
this effect among speciﬁc symptom domains, since it showed highlyFig. 3.Mean (±SEM, N=6 alleles) frequency of the six discriminating alleles (combined)
for the ﬁve groups indicated.signiﬁcant overall protective effects for Pain, Fatigue, Neurological-
Cognitive-Mood domains. Remarkably, the effect of each allele on
symptom severity in each one of these domains was protective, as evi-
denced by the universally negative partial regression coefﬁcients in
those three separate regression analyses. In contrast, the effect was
not signiﬁcant for the Skin, Gastrointestinal and Respiratory domains.
The comparison of the observed allele frequencies to those reported
in published databases (Ovsyannikova et al., 2005; Rossman et al., 2003;
Skibola et al., 2012) (Figs. 3–5) documented an additional ﬁnding,
namely that both GWI and controls differed systematically and in
opposite directions (higher for controls, lower for GWI, Figs. 4 and 5)
with respect to the published allele frequencies. This suggests the
following hypothesis regarding the role of the six discriminating alleles
we identiﬁed. First, we assume that the population of GW-era veterans
came from a larger population whose allele frequencies would be very
similar to those reported in the three databases we used in this study.
This is a reasonable assumption. Second, it is known that GW veterans
were administered various vaccines, possibly together and/or multiply
(Institute of Medicine, 2000; Petersdorf et al., 1996; Schwartz et al.,
1997; Steele, 2000) and they were exposed to various chemical agents
(Institute of Medicine, 2000; Steele et al., 2015). Third, a proportion of
GW veterans developed GWI consisting of chronic symptoms affecting
multiple organ systems (Fukuda et al., 1998; Institute of Medicine,
2006, 2010; Kang et al., 2009; Kelsall et al., 2009; Steele, 2000), mostly
affecting veterans who were deployed but also present in non-
deployed or minimally exposed veterans (Steele, 2000). Based on
those facts, we hypothesize that vaccinations and/or chemical expo-
sures of GW era veterans served as environmental triggers (“hits”)
that contributed to developing GWI in genetically (HLA) “vulnerable”Fig. 5.Mean ln(ω) for the control and GWI groups for each database. (See text for details.)
Table 5
Haplotypes reported for the SF database at the “Allele*Frequencies in Worldwide
Populations” website (http://www.allelefrequencies.net/). No haplotypes reported for
alleles DPB1*06:01 and DRB1*08:11.
Haplotypes Frequency
(%)
A. DQB1*02:02
1 DRB1*07:01-DQA1*02:01-DQB1*02:02 8.9
2 DRB1*07:01-DRB4*01:01-DQA1*02:01-DQB1*02:02-DPB1*04:01 2.4
3 DRB1*07:01-DRB4*01:01-DQA1*02:01-DQB1*02:02-DPB1*04:02 1.3
4 DRB1*07:01-DRB4*01:01-DQA1*02:01-DQB1*02:02-DPB1*11:01 1.1
5 DRB1*07:01-DRB4*01:01-DQA1*02:01-DQB1*02:02-DPB1*17:01 1.8
B. DRB1*13:02
1 DRB1*13:02-DQA1*01:02-DQB1*06:04 3.0
2 DRB1*13:02-DQA1*01:02-DQB1*06:09 1.4
3 DRB1*13:02-DRB3*03:01-DQA1*01:02-DQB1*06:04-DPB1*04:01 1.3
C. DRB1*01:01
1 DRB1*01:01-DQA1*01:01-DQB1*05:01 6.4
D. DPB1*01:01
1 DRB1*03:01-DRB3*01:01-DQA1*05:01-DQB1*02:01-DPB1*01:01 3.90
84 A.P. Georgopoulos et al. / EBioMedicine 3 (2016) 79–85veterans. Speciﬁcally, we propose that the presence of certain HLA al-
leles in higher frequencies conferred protection, whereas their relative
paucity conferred vulnerability. This, in turn, resulted in the two distinct
subpopulations of our study, namely control, deployed GW veterans
with higher allele frequencies and absence of GWI on the one hand,
and deployed GW veterans with lower frequencies and presence of
GWI (Fig. 3). It should be noted that both vaccinations (Hotopf et al.,
2000; Israeli, 2012; Toubi, 2012; Rook and Zumla, 1997) and chemical
exposures (Moss, 2013) have been implicated previously as contribut-
ing factors for the development of GWI. The results of our study simply
add a genetic susceptibility framework within which the effects of the
factors above could be interpreted and investigated in future work.
The nature of this postulated protection is likely to relate to autoim-
mune aswell as inﬂammatory processes, since HLA has been implicated
in both (Trowsdale and Knight, 2013; Johnson et al., 2013; Blackwell
et al., 2009). In addition, HLA genetic underpinnings in immune re-
sponses to vaccines have been well established (Ovsyannikova et al.,
2006; Ovsyannikova and Poland, 2011; Poland et al., 2007, 2008a,
2008b). Speciﬁc HLAmakeup could thus manifest as autoimmune reac-
tions, aberrant immune response to vaccinations, and/or increased sus-
ceptibility to infections (Nicolson, 1998); all three of them have been
implicated in GWI.
A major limitation of our study is the small number of participants
studied which, nevertheless, yielded systematic, signiﬁcant and robust
differences between the control and GWI groups but also between
those two groups and published HLA allele databases. In this context,
it is especially noteworthy that high correct classiﬁcation rateswere ob-
tained in our extensive bootstrap analyses and permutation analyses
(Sanchez, 1974) which documented the robustness of our results, i.e.
their extension to larger sample populations. However, extensive boot-
straps cannot substitute for validation in new, independent samples,
which remains to be done. Finally, it is reasonable to assume that the
six alleles identiﬁed in the present study are only part of a protective
HLA makeup. We anticipate that a similar but large scale study will
identify more such alleles and will provide a ﬁrm background to inves-
tigate the molecular mechanisms by which such protection/vulnerabil-
ity may be mediated (Wahren-Herlenius and Dorner, 2013).
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